caa a22 4500 445335394 CHVBK 20180317142753.0 cr unu---uuuuu 170323e20111001xx s 000 0 eng 10.1245/s10434-011-1722-3 doi (NATIONALLICENCE)springer-10.1245/s10434-011-1722-3 Trends of Retroperitoneal Lymphadenectomy Use in Patients with Nonseminomatous Germ Cell Tumor of the Testis: A Population-Based Study [Elektronische Daten] [Maxine Sun, Firas Abdollah, Lars Budaüs, Daniel Liberman, Zhe Tian, Monica Morgan, Rupinder Johal, Jan Schmitges, Shahrokh Shariat, Francesco Montorsi, Markus Greafen, Paul Perrotte, Pierre Karakiewicz] Background: Retroperitoneal lymphadenectomy (RPLND), chemotherapy, and active surveillance represent treatment options for patients with nonseminomatous germ-cell tumors of the testis (NSGCTT). Our objective was to assess the utilization rate of RPLND in patients with NSGCTT. Methods: Within the Surveillance, Epidemiology and End Results (SEER) cohort, 4,620 and 1,671 patients with stage I and II NSGCTT were diagnosed between the years 1988 and 2006. Univariable and multivariable logistic regression analyses were performed to test the predictors of RPLND use in respectively patients with stage I and II NSGCTT. Results: The rate of RPLND according to stage I and II was 27 and 58%, respectively. In patients with stage I disease, the rate of RPLND decreased from 39% in 1988-1995 to 18% in 2004-2006 (P<0.001), and remained stable for stage II patients (62-56%, P=0.2). Regional variability existed regarding the rate of RPLND use only in stage I (Utah: 51% vs. Louisiana: 16%). Multivariable analyses performed in stage I NSGCTT revealed that year of diagnosis, SEER registry, and age were significant predictors of RPLND use. However, none of these variables achieved statistical significance within stage II NSGCTT patients. Conclusions: In patients with stage I NSGCCT, the RPLND utilization rate decreased during the study span. This observation may be ascribed to wider use of surveillance or chemotherapy. No temporal difference was recorded in patients with stage II NSGCCT. Society of Surgical Oncology, 2011 Sun Maxine Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center (CHUM), Montreal, QC, Canada aut Abdollah Firas Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center (CHUM), Montreal, QC, Canada aut Budaüs Lars Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center (CHUM), Montreal, QC, Canada aut Liberman Daniel Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center (CHUM), Montreal, QC, Canada aut Tian Zhe Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center (CHUM), Montreal, QC, Canada aut Morgan Monica Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center (CHUM), Montreal, QC, Canada aut Johal Rupinder Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center (CHUM), Montreal, QC, Canada aut Schmitges Jan Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center (CHUM), Montreal, QC, Canada aut Shariat Shahrokh Department of Urology, Weill Medical College of Cornell University, New York, New York, USA aut Montorsi Francesco Department of Urology, Vita Salute San Raffaele University, Milan, Italy aut Greafen Markus Martini-Clinic, Prostate Cancer Center, Hamburg-Eppendorf, Hamburg, Germany aut Perrotte Paul Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center (CHUM), Montreal, QC, Canada aut Karakiewicz Pierre Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center (CHUM), Montreal, QC, Canada aut Annals of Surgical Oncology Springer-Verlag 18/10(2011-10-01), 2997-3004 1068-9265 18:10<2997 2011 18 10434 https://doi.org/10.1245/s10434-011-1722-3 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1245/s10434-011-1722-3 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Sun Maxine Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center (CHUM), Montreal, QC, Canada aut NATIONALLICENCE 700 1- Abdollah Firas Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center (CHUM), Montreal, QC, Canada aut NATIONALLICENCE 700 1- Budaüs Lars Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center (CHUM), Montreal, QC, Canada aut NATIONALLICENCE 700 1- Liberman Daniel Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center (CHUM), Montreal, QC, Canada aut NATIONALLICENCE 700 1- Tian Zhe Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center (CHUM), Montreal, QC, Canada aut NATIONALLICENCE 700 1- Morgan Monica Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center (CHUM), Montreal, QC, Canada aut NATIONALLICENCE 700 1- Johal Rupinder Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center (CHUM), Montreal, QC, Canada aut NATIONALLICENCE 700 1- Schmitges Jan Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center (CHUM), Montreal, QC, Canada aut NATIONALLICENCE 700 1- Shariat Shahrokh Department of Urology, Weill Medical College of Cornell University, New York, New York, USA aut NATIONALLICENCE 700 1- Montorsi Francesco Department of Urology, Vita Salute San Raffaele University, Milan, Italy aut NATIONALLICENCE 700 1- Greafen Markus Martini-Clinic, Prostate Cancer Center, Hamburg-Eppendorf, Hamburg, Germany aut NATIONALLICENCE 700 1- Perrotte Paul Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center (CHUM), Montreal, QC, Canada aut NATIONALLICENCE 700 1- Karakiewicz Pierre Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center (CHUM), Montreal, QC, Canada aut NATIONALLICENCE 773 0- Annals of Surgical Oncology Springer-Verlag 18/10(2011-10-01), 2997-3004 1068-9265 18:10<2997 2011 18 10434 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer